COMMUNIQUÉS West-GlobeNewswire

Ajax Therapeutics Receives Orphan Drug Designation from the U.S. FDA for AJ1-11095 for the Treatment of Myelofibrosis
10/12/2025
AJ1-11095 is a first-in-class Type II JAK2 inhibitor currently in a Phase 1 study for the treatment of patients with myelofibrosis, previously treated with a Type I JAK2 inhibitor NEW YORK and CAMBRIDGE, Mass., Dec. 10 [...]
PetMeds Announces Holiday Collection: Wellness-Focused Gifts for Pets and the People Who Love Them
10/12/2025
DELRAY BEACH, Fla., Dec. 10, 2025 (GLOBE NEWSWIRE) -- PetMed Express, Inc., d/b/a PetMeds and parent company of PetCareRx, (Nasdaq: PETS) (the “Company”), today unveiled its new Holiday Collection, a curated selection [...]
DARE to PLAY™ Sildenafil Cream Now Available for Pre-Order by Prescription: First Evidence-Based Topical Arousal Cream for Women Begins Commercial Rollout in Select States via 503B Outsourcing Facility
10/12/2025
Developed and evaluated specifically for women, DARE to PLAY™ Sildenafil Cream is a first-of-its-kind female arousal cream, a non-hormonal topical cream shown in clinical studies to increase genital blood flow in 10–15 [...]
Accrete Health Partners Launches Partnership with Atalan to Co-develop Groundbreaking Patient Experience Intelligence Module
10/12/2025
Strategic Co-Development Partnership Expands Relationship between Bon Secours Mercy Health and Atalan to Unify Workforce and Patient Experience Analytics PHILADELPHIA, Dec. 10, 2025 (GLOBE NEWSWIRE) -- Atalan , the [...]
Barinthus Bio Announces Update on Phase 1 AVALON Clinical Trial of VTP-1000 for the Treatment of Celiac Disease
10/12/2025
VTP-1000, an antigen-specific immunotherapy to treat celiac disease, showed a dose-dependent pharmacological effect in the SAD portion of the trial VTP-1000 was well-tolerated with no treatment-related SAEs The MAD [...]
Fulcrum Therapeutics Announces Pricing of Upsized $175.0 Million Public Offering of Common Stock and Pre-Funded Warrants
10/12/2025
CAMBRIDGE, Mass., Dec. 10, 2025 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc. ® (“Fulcrum”) (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of [...]
Avance Clinical Launches Diversity in STEM Scholarships Across Australia and North America
10/12/2025
ADELAIDE, Australia, Dec. 10, 2025 (GLOBE NEWSWIRE) -- Avance Clinical, the award-winning global CRO for biotechs, has announced the launch of its new Diversity in STEM Scholarships , a global initiative designed to [...]
BriaCell Presents Outstanding Phase 2 Survival & Promising Phase 3 Clinical Data at SABCS® 2025
10/12/2025
BriaCell presents positive clinical data in three posters at the San Antonio Breast Cancer Symposium (SABCS ® ) Phase 3 study of Bria-IMT™ plus immune check point inhibitor (CPI) continues to support biomarkers to [...]
Medicenna Updates MDNA11 Clinical Trial Results at the ESMO-IO Congress 2025, Further Bolstering its Anti-Tumor Activity in Advanced Solid Tumors
10/12/2025
MDNA11 demonstrates durable anti-tumor activity in phase-2 eligible expansion cohorts, enriched for immune checkpoint resistant melanoma, MSS endometrial cancer, MSI-H and TMB-H cancers, in each case exceeding objective [...]
ProMIS Neurosciences Announces New Peer-Reviewed Publication Highlighting Selective Targeting of Toxic Oligomers for Potential Clinical Benefit and Reduced ARIA Risk
10/12/2025
Results support the potential of PMN310 to improve outcomes by selectively targeting oligomers and avoiding binding to monomer and plaque ProMIS on track to complete enrollment in PRECISE-AD trial in Alzheimer’s disease [...]
Kane Biotech Receives Health Canada Approval for revyve® Antimicrobial Wound Gel Spray
10/12/2025
WINNIPEG, Manitoba, Dec. 10, 2025 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V:KNE) (“Kane Biotech”, “Kane” or the “Company”) today announces that Health Canada has approved its revyve ® Antimicrobial Wound Gel Spray [...]
Sagimet’s License Partner Ascletis Announced Acceptance of New Drug Application for Denifanstat for the Treatment of Moderate to Severe Acne by China’s National Medical Products Administration
10/12/2025
SAN MATEO, Calif., Dec. 10, 2025 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic and fibrotic [...]
Microbix Launches New Products to Support H3N2 Flu Testing
10/12/2025
Test-Controls & Reference Materials for Labs & Test-Makers MISSISSAUGA, Ontario, Dec. 10, 2025 (GLOBE NEWSWIRE) -- Microbix Biosystems Inc. ( TSX: MBX, OTCQX: MBXBF, Microbix ® ), a life sciences innovator, [...]
BioStem Technologies® to Debut American Amnion™ at the 2025 Desert Foot Multi-Disciplinary Limb Salvage and Wound Care Conference
10/12/2025
Expanding its Portfolio with American Amnion to Serve the Wound Care Needs of Our Veterans POMPANO BEACH, Fla., Dec. 10, 2025 (GLOBE NEWSWIRE) -- BioStem Technologies, Inc. (OTC: BSEM), a leading MedTech company [...]
PsiThera Unveiled with Newly Appointed CEO and $47.5 Million Series A to Advance Oral Medicines for Validated I&I Targets
10/12/2025
$47.5 million Series A financing led by Samsara Biocapital and Lightstone Ventures to advance PsiThera’s growing pipeline, starting with multiple clinically validated TNF superfamily preclinical programs Biotech veteran [...]
Telix and Varian Announce Strategic Theranostics-EBRT Clinical Collaboration
10/12/2025
MELBOURNE, Australia and PALO ALTO, Calif., Dec. 10, 2025 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) today announces a strategic clinical collaboration with Varian, a Siemens [...]
MediWound Reports New Clinical Data Demonstrating NexoBrid®’s Effectiveness in Preventing Traumatic Tattoos After Abrasion and Blast Injuries
10/12/2025
MediWound Reports New Clinical Data Demonstrating NexoBrid ® ’s Effectiveness in Preventing Traumatic Tattoos After Abrasion and Blast Injuries Prospective clinical data show NexoBrid ® removes embedded particles in [...]
BlossomHill Therapeutics Announces $84 Million Financing to Accelerate Clinical-Stage Pipeline of Intelligently Designed Cancer Medicines Including First-in-class Macrocyclic OMNI-EGFR™ Inhibitor for NSCLC
10/12/2025
Proceeds to further advance clinical development of BH-30643, a first-in-class, macrocyclic, CNS-active, mutant-selective OMNI-EGFR TM inhibitor for EGFR-mutant NSCLC, and BH-30236, a novel macrocyclic CLK inhibitor [...]
Sanuwave to Participate in the 44th Annual J.P. Morgan Healthcare Conference
10/12/2025
EDEN PRAIRIE, Minn., Dec. 10, 2025 (GLOBE NEWSWIRE) -- Sanuwave Health, Inc. (the "Company" or "Sanuwave”) (NASDAQ: SNWV), a leading provider of FDA-approved next-generation wound care products, is pleased to announce [...]

Pages